[THE INVESTOR] Korean pharma company BioLeaders will list on the secondary bourse KOSDAQ on July 7.
Established in 1999, the company develops drugs for immune disorders and other incurable diseases.
 |
CEOs of BioLeaders: Sung Moon-hee (left) and Kim Sang-suk |
Prior to listing on the tech-heavy KOSDAQ, BioLeaders was traded on KONEX -- a securities exchange exlusively for small and medium enterprises and venture companies.
It will issue 1.2 million shares within the range of 11,000 won (US$9.5) to 15,000 won per share. The company expects to raise 13.2 billion won to 18 billion won.
By Ahn Sung-mi (
sahn@heraldcorp.com)
